Side-by-side · Research reference

HGH Fragment 176-191vsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED28/59 cited

BPhase 2HUMAN-REVIEWED8/46 cited

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

HGH Fragment 176-191

TB-500

Primary target

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

N/A — does not interact with GH/IGF-1 axis

Endogenous protein at baseline; supplementation amplifies

Origin

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

Not reported in available studies

—

02Dosage Protocols

Parameter

HGH Fragment 176-191

TB-500

Animal dose (oral)

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

—

Animal dose (IP)

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

—

Human equivalent dose

Not established — no published human RCTs

—

Frequency

Once daily (animal models)

2× per week (loading); then 1× per week (maintenance)

Evidence basis

Animal studies only

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration tested

14–19 daysHeffernan 2001 Ng 2000

—

Detection window

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

—

Oral bioavailability

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

—

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Lower / starter dose

—

1 mg per injection

Duration

—

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

—

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

—

Evening or pre-rest preferred (anecdotal)

Half-life

—

~2 hours (estimated; tissue uptake longer)

03Metabolic / Fat Loss Evidence

Parameter

HGH Fragment 176-191

TB-500

Primary fat target

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

—

Weight gain reduction

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

—

Body fat reduction

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

—

Lipolytic activity

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

—

Beta-3 AR expression

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

—

Insulin sensitivity

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

—

IGF-1 impact

No elevation — fragment does not activate GH/IGF-1 axis

—

Beta-3 AR dependency

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

—

Route of administration

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

—

Human evidence

None published — pre-clinical only

—

04Side Effects & Safety

Parameter

HGH Fragment 176-191

TB-500

Insulin sensitivity

No adverse effects observed in euglycemic clamp (animal)Ng 2000

—

GH/IGF-1 axis

No activation — avoids diabetogenic effects of full GHNg 2000

—

Human safety data

Not available — no published human trials

—

WADA status

Banned as performance-enhancing drugCox 2015

—

Metabolic profile

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

—

Injection site reaction

—

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

HGH Fragment 176-191

·Absence of human safety data — experimental use only

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

HGH Fragment 176-191

TB-500

1. Route

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Frequency

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Duration

Animal protocols: 14–19 days. Human duration not established — no published trials.

Evening or pre-sleep is most common anecdotal timing.

4. Storage

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Detection

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

HGH Fragment 176-191

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair